Dr. Fred R. Hirsch, MD, PhD, is honored with the Addario Foundation Lectureship Award for his contributions to lung cancer research, education, and service. The award recognizes his dedication to eliminating lung cancer worldwide through translational-clinical research.
The study of over 160,000 postmenopausal women revealed no significant link between lung cancer risk and reproductive history or hormone therapy. However, some subgroups showed reduced risks for specific types of lung cancer, emphasizing the need for further research into complex relationships.
Physical activity has been shown to reduce symptoms, increase exercise tolerance, and improve quality of life in lung cancer patients. Additionally, increased physical activity may also benefit lung cancer survivors by improving exercise capacity and symptom burden.
Researchers found that patients with stage I non-small cell lung cancer (NSCLC) and low tumor metabolic activity have increased overall survival. A diagnostic test using fluorodeoxyglucose positron emission tomography (FDG/PET) can help identify patients who may benefit from post-surgical chemotherapy.
The study found a significant decline in early recall rates from 20% to 3-4% in subsequent rounds, while lung cancer detection rates decreased by 50%. A well-organized screening program with access to previous images and results is crucial to manage false positives.
Patients treated at high-volume facilities for stage III non-small cell lung cancer (NSCLC) have longer overall survival when receiving definitive concurrent chemotherapy and radiation therapy. Studies show improved outcomes for patients treated at these centers, regardless of academic or community status.
An interactive online education tool has been developed to help practicing oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) by providing feedback from an expert panel. The tool integrates clinical, histological, and molecular features into treatment plans, leading to a change in treatment cho...
Researchers found elevated levels of malignant mesothelioma cases in southern Nevada counties due to environmental exposure to carcinogenic mineral fibers. The incidence is higher in locations with known industrial exposure, with a male-to-female ratio of 2:1 in affected counties.
Researchers found that rare EGFR mutations in non-small cell lung cancer (NSCLC) have distinct impacts on disease outcome and therapy response. Classic EGFR mutations were associated with better overall survival and higher TKI therapy response rates compared to rare mutations, which were linked to tobacco smoking and poorer prognosis.
The NELSON trial found that individuals with better health profiles and younger age were less likely to participate, but the study's findings remain relevant due to modest differences. The trial showed a higher mortality rate among eligible non-participants compared to participants.
A study found that multiplexed genetic screening for EGFR and ALK gene rearrangements followed by molecularly-guided treatment is cost-effective compared to standard chemotherapy. The approach offers better outcomes in terms of quality-adjusted life years gained and life-years, making it a valuable option for patients with NSCLC.
Researchers used targeted NGS to identify genetic alterations in genes involved in DNA repair, cell survival, and proliferation pathways. The study found that accumulated mutations correlate with tumor progression and decreased survival rates in patients with advanced malignant lung cancer. The results highlight the potential of NGS to...
A nationwide survey of 2200 French adults reveals significant knowledge gaps about lung cancer, including misconceptions about screening, treatment options, and prognosis. The study emphasizes the need for public education to address these gaps and improve outcomes.
Researchers found that pretreatment interstitial lung disease significantly increases the risk of developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy. The study's results suggest that clinicians should be cautious when considering SBRT f...
A risk stratification model based on lymph node characteristics confirms the true lack of lung cancer in sampled nodes. The model categorizes low-risk nodes with a high chance of being truly negative, while high-risk nodes have a significant false-negative rate.
Low preoperative serum squamous cell carcinoma antigen levels and absence of tumor invasion into the pleura or blood vessels are independent prognostic factors for patients with peripheral squamous cell carcinomas of the lung. These factors are associated with longer overall survival and reduced disease recurrence.
A European multicenter harmonization study reveals that standardized semi-quantitative anaplastic lymphoma kinase (ALK) IHC is reliable and comparable to FISH testing for detecting ALK protein expression. The study showed 100% concordance among institutions on 15 well-characterized NSCLC specimens, making IHC a potential stand-alone test.
A novel software application, CANARY, can automatically analyze high-resolution CT images to classify early-stage non-small cell lung cancer patients into risk groups. The tool was developed at Mayo Clinic and demonstrated accurate stratification of patients into categories with different 5-year disease-free survival outcomes.
The NCI/FDA workshop resulted in the development of two innovative clinical trials, Lung-MAP and ALCHEMIST, which employ a 'Master Protocol' approach to improve patient outcomes. These trials aim to accelerate the development of targeted therapies for lung cancer by integrating multiple sub-studies based on genomic profiles.
Researchers found modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy, but no clinically significant cardiac events. The study suggests that longer follow-up and increased dose range may reveal the impact of radiation on late RT-related toxicity.
A new study found that high-risk individuals screened for early-stage lung cancer using low-dose computed tomography (LDCT) can reduce treatment costs by up to 85%, resulting in a significant reduction in mortality rates and improved patient outcomes. The average cost per-person for LDCT screening was $453, while the mean cost for diag...
Researchers found high concordance (94%) between EGFR mutations in plasma-derived ctDNA and tumor tissue in NSCLC patients. This suggests that a single plasma sample may be sufficient for mutation status assessment when tumor tissue is unavailable.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
Researchers identify RET M918T mutation in SCLC tumors, which drives increased ERK signaling and MYC expression. The mutation makes cells sensitive to tyrosine kinase inhibitors ponatinib and vandetanib.
ROS1 gene fusions were detected in 12 out of 492 specimens examined for lung adenocarcinoma using RT-PCR and IHC tests. ROS1 positive patients are significantly younger than the entire population, but there are no associations with gender or smoking history.
Increased use of less toxic chemotherapy treatments in advanced NSCLC is associated with higher overall survival. The study found a significant increase in survival rates among patients receiving second-line therapy, with median overall survival ranging from 3.9 to 11.8 months.
A recent study found that a 5-year low-dose computed tomography (LDCT) screening protocol can detect lung cancer effectively, with a high proportion of cancers being treated and good long-term survival rates. The results show improved diagnostic performance compared to other studies, including the National Lung Cancer Screening Trial.
A systematic review of 8215 studies found that low-dose computed tomography (LDCT) screening does not significantly influence overall quality of life or result in long-term anxiety or distress. However, positive results can lead to short-term increases in distress levels.
Researchers found a rare hereditary syndrome associated with a 31% risk of disease in never-smokers carrying the germline EGFR T790M mutation. The study highlights the need for increased surveillance and screening for affected carriers, regardless of smoking status.
A recent study found that female hormone therapy, particularly estrogen plus progesterone, significantly improved survival among women with non-small cell lung cancer. The combination of hormone therapy and long-term use showed the most notable improvements in median survival time.
A study found significant discrepancies between fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) results for ALK testing, leading to the detection of approximately 25% of ALK-positive cases. The findings support the need for combined testing using both FISH and IHC methods.
Researchers have developed a novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) using quantitative (q)RT-PCR. The assay overcomes limitations of existing methods, including cost and interpretation challenges, with high sensitivity and ease of use.
A recent study found that EGFR mutations are prevalent among the Asian population, with a frequency of 51.4% in stage IIIB or IV adenocarcinomas of the lung. The mutation was more common among women and never-smokers than previously reported.
The cumulative success rate for new agents in advanced NSCLC is lower than industry estimates, but biomarker- and receptor-targeted therapies substantially increase success rates. Biomarker-targeted therapy shows a 62% cumulative success rate, nearly six times higher than non-biomarker targeted trials.
The International Association for the Study of Lung Cancer (IASLC) awarded five people Advocacy Travel Awards to support their attendance at the 2013 World Conference on Lung Cancer in Sydney. The awards provide conference registration, accommodations, a free IASLC Membership, and a travel stipend.
A new set of evidence-based guidelines recommend lung cancer screening for high-risk populations in Ontario using low-dose computed tomography (LDCT). The guidelines suggest annual screening for two years, followed by biennial screenings until a negative result is obtained. The recommended parameters for LDCT include 120 to 140 kVp and...
A prospective cohort study of 81,697 racially diverse adults found that lung cancer survival between black and white patients was similar when demographic factors and smoking were controlled. The study aimed to address racial disparities in lung cancer survival rates.
Researchers recommend accelerated radiotherapy as standard treatment for un-resected non-small cell lung cancer patients not receiving concurrent chemo-radiotherapy, citing its efficiency over current practice. However, cost-effectiveness of different modified schemes remains uncertain and requires further research.
A recent retrospective study found that chemotherapy improves median survival among elderly patients with small cell lung cancer (SCLC) by more than 6 months. The study analyzed data from 10,428 patients aged 65 and older who received chemotherapy between 1992 and 2001.
Researchers in Canada found that funding from the pharmaceutical industry significantly decreased EGFR mutation testing after it was discontinued. The Canadian healthcare system lacked resources for implementing a national policy, leading to a substantial drop in test requests.
Researchers have identified Ephrin B2 as a promising target for treating malignant pleural mesothelioma, a rare and aggressive form of lung cancer. The study found that EPHB2 is significantly overexpressed in tumor tissue compared to normal peritoneum, suggesting its potential as a biomarker for early diagnosis and treatment.
Researchers found that obese patients initially had superior outcomes in terms of overall survival compared to normal-weight and overweight patients. However, their risk of death from any cause significantly increased once they were on the study longer than 16 months, indicating a limited time benefit of obesity in lung cancer patients.
Researchers have developed two new methodologies to determine ALK status in non–small-cell lung cancer (NSCLC) patients. The first method improves IHC assay sensitivity using a novel hapten and tyramide amplification, detecting low levels of ALK protein expression. The second method combines brightfield IHC with in situ hybridization f...
Researchers developed a highly accurate method to detect ALK-rearranged non-small cell lung cancer using immunocytochemistry. The study found that this method had high sensitivity and specificity, making it suitable for prescreening NSCLC patients.
A study of 582 patients with stage I non-small cell lung cancer (NSCLC) found SBRT to be safe and effective, with a three-year freedom from local progression rate of 79.6%. The biological effective dosage was the most significant factor influencing outcomes.
Researchers found that PET-CT improved staging accuracy and intrathoracic disease identification in limited-stage small-cell lung cancer patients. This led to an improvement in overall survival rates compared to those not staged with PET-CT.
A recent study found that lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor (ER) overexpression. The researchers observed a higher percentage of these genetic abnormalities in patients who had not previously smoked, suggesting potential new treatment targets for this group.
Researchers evaluate immunohistochemistry for detecting ALK rearrangement in lung adenocarcinoma, finding it a reliable and cost-effective method. The study suggests that IHC can effectively detect ALK rearrangement and identify suitable candidates for targeted therapy.
A recent study published in the Journal of Thoracic Oncology found that digital chest tomosynthesis (DT) holds promise as a first-line lung cancer screening tool. DT improved sensitivity in detecting lung nodules compared to conventional chest radiography, while providing lower costs and radiation dosages.
Sarcomatoid lung carcinomas are rare and aggressive diseases resistant to chemotherapy. Researchers found higher levels of programmed death ligand-1 (PD-L1) in these tumors, which may lead to the use of anti-PD-1/PD-L1 targeted therapies. This discovery supports potential novel immunotherapy approaches for this difficult-to-treat disease.